The Microbiotics Company
Innovative microbiotic active ingredients
Active ingredient line stimulans® - Skin microbiome
We have developed stimulans®, an active ingredient from the lactic acid bacteria Lactobacillus brevis DSM17250. It stimulates the growth of the protective bacteria (Staphylococcus epidermidis) on the skin, strengthening these beneficial skin bacteria and healthy skin functions and thus reducing inflammatory germs (e.g. Staphylococcus aureus).
This restores the skin microbiome to its healthy balance. It significantly reduces inflammation symptoms and improves the skin appearance in skin diseases such as atopic dermatitis , psoriasis, acne and rosacea. The active ingredient and active principle are patent-protected.
Active ingredient line salvans® - Throat microbiome
We obtain the active ingredient salvans® from the bioactive lactic acid Lactobacillus crispatus DSM25988 bacteria, which has a very specific effect against the inflammatory Streptococcus pyogenes bacteria in the throat. Salvans® reliably reduces harmful germs, reduces the risk of inflammation in the throat and thus accelerates the healing process. At the same time, it does not affect the beneficial bacteria in the throat.
salvans® provides safe prevention for throat problems.
The active ingredient salvans® is protected by patent.
Active ingredient line ventrisana® - Mouth/Stomach microbiome
With the active ingredient ventrisana® from the lactic acid bacterium Lactobacillus reuteri DSM17648, a medical device is available that specifically binds the “stomach germ” Helicobacter pylori and removes it from its habitat. If left untreated, H. pylori infection leads to periodontal problems as well as gastritis, heartburn and, in the worst case, stomach ulcers and stomach cancer.
ventrisana® offers safe and specific prevention against chronic gum inflammation (periodontal chewing gum) and H. pylori-related stomach problems. The active ingredient ventrisana® is protected by patent.
Active ingredient line aureosan® Wound treatment/MRSA
With aureosan®, we have found an active ingredient in the lactic acid bacterium Lactobacillus gasseri DSM25908 that effectively and precisely binds Staphylococcus aureus, including resistant strains (MRSA), and removes it from the skin and mucosal lesions. aureosan® is suitable for the treatment of chronic wounds as well as for the cleansing of skin areas colonised by S. aureus, such as those found in atopic dermatitis and acne skin.
aureosan® also provides a solution for increasingly urgent hygiene requirements in hospitals, clinics and care facilities, when multi-resistant germs in patients, nursing staff and visitors need to be removed non-antibiotically.
aureosan® is currently in the clinical trial stage. The active ingredient aureosan® is protected by patent.